NEW YORK, NY / ACCESS Newswire / March 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO ...

LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

marking a shift in response to the discontinuation of the FIRCE-1 Phase 2 study of firicabtagene autoleucel (firi-cel). While the firicabtagene autoleucel program is being phased out, CARGO is ...

CARGO announced in a press release issued on January 29, 2025, that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL ...

CARGO intends to present an analysis of the FIRCE-1 Phase 2 study at a future medical conference. CARGO Therapeutics, Inc. is a clinical-stage biotechnology company advancing next-generation ...

CARGO announced in a press release issued on January 29, 2025, that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL ...

CARGO Therapeutics , Inc. (NASDAQ:CRGX), a clinical-stage biotech company currently valued at $628 million, announced today the discontinuation of its Phase 2 clinical study, FIRCE-1, for the ...

Pomerantz LLP is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("Cargo" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

China has announced the successful completion of its first intercity cargo drone flight, marking a significant step in integrating artificial intelligence technologies into the aviation sector.